The therapeutic objective of GH control below 2·5 ng/ml and concentrations of IGF-1 within the normal range is widely used, as patients with acromegaly who have this level of control have a mortality rate similar to that of the general population.18–23 This also showed a trend to superiority on lan ATG, with 40% patients showing good biochemical control, rising from 35% on Lan MP. This evidence concerns the gene IGF1 and acromegaly.